UCB And Sanofi To Target Small Molecules For Immune-Mediated Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
The $139 million discovery and development collaboration announced between the two European pharmaceutical companies will use an innovative approach to identify small molecule modulators of therapeutically useful biological pathways.